A multicenter phase Ib/II study of liposomal-irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) with nivolumab as second-line therapy for patients with advanced biliary tract cancer (BilT-03).

Authors

Vaibhav Sahai

Vaibhav Sahai

University of Michigan, Ann Arbor, MI

Vaibhav Sahai , Kent A. Griffith , Bruce Shih-Li Lin , Heloisa P. Soares , Sreenivasa R Chandana , Oxana V. Crysler , Thomas Enzler , Mark Zalupski

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03785873

DOI

10.1200/JCO.2022.40.4_suppl.438

Abstract #

438

Poster Bd #

Online Only

Abstract Disclosures